| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5701362 | Journal of Cancer Policy | 2017 | 15 Pages |
Abstract
With national formularies analyzed for over 80% of all LMICs, this study found that most LMICs listed under half of cancer medications considered by the WHO to be essential. LMIC decision-making for policies related to cancer drug access may be heavily influenced by economic development, as well as by the high prevalence of certain cancer risk factors. The results from this study suggest that LMICs are generally ill-prepared to adequately provide essential treatment for their rapidly rising numbers of cancer patients.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Raphael E. Cuomo, Tim K. Mackey,